Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 28, 2023 12:30 ET | Source: Pharma Equity Group A/S

Status for Selskabets tilgodehavende hos Portinho S.A.

28. november 2023 Meddelelse nr. 46 Status for Selskabets tilgodehavende hos Portinho S.A. Selskabets bestyrelse, valgt ind i forbindelse med at Selskabet blev omdannet til en...
November 28, 2023 12:30 ET | Source: Pharma Equity Group A/S

Status of the Company's receivable from Portinho S.A.

November 28, 2023 Company Announcement no. 46 Status of the company's receivable from Portinho S.A. The Company's Board of Directors, which was elected in connection with the...
November 28, 2023 08:56 ET | Source: Pharma Equity Group A/S

Finanskalender for 2024

28. november 2023 Pressemeddelelse Pharma Equity GroupFinanskalender for 20244. martsFrist for aktionærforslag - Ordinær generalforsamling20. marts Årsrapport 202316. aprilOrdinær...
November 28, 2023 08:56 ET | Source: Pharma Equity Group A/S

2024 Financial Calendar

28 November 2023 News Release Pharma Equity Group2024 Financial CalendarMarch 4Deadline for shareholder proposals - Annual General meetingMarch 20 Annual Report 2023April 16Annual General...
November 16, 2023 06:17 ET | Source: Pharma Equity Group A/S

Pharma Equity Group’s datterselskab (Reponex Pharmaceuticals A/S) opnår de primære endpoints i selskabets kliniske fase 2 studie med lægemiddelkandidaten RNX-051.

16. november 2023 Selskabsmeddelelse nr. 45 Pharma Equity Group’s datterselskab (Reponex Pharmaceuticals A/S) opnår de primære endpoints i selskabets kliniske fase 2 studie med lægemiddelkandidaten...
November 16, 2023 06:17 ET | Source: Pharma Equity Group A/S

Pharma Equity Group’s subsidiary (Reponex Pharmaceuticals A/S) meets the primary endpoints in the phase-2 clinical trial of the drug candidate RNX-051.

16 November 2023 Company Announcement no. 45 Pharma Equity Group’s subsidiary (Reponex Pharmaceuticals A/S) meets the primary endpoints in the phase-2 clinical trial of the drug candidate RNX-051. ...
November 16, 2023 02:26 ET | Source: Pharma Equity Group A/S

Konsolideret delårsrapport 1. januar – 30. september 2023

Konsolideret delårsrapport 1. januar – 30. september 2023 16. november 2023 Selskabsmeddelelse nr. 44 Hovedpunkter (ni-måneders rapport afsluttet 30. september 2023) Bestyrelsen og direktionen i...
November 16, 2023 02:26 ET | Source: Pharma Equity Group A/S

Consolidated interim report 1 January – 30 September 2023

Consolidated interim report 1 January – 30 September 2023 16 November 2023 Company Announcement no. 44 Key points (nine-month report ended 30 September 2023) On 16 November 2023, the Board of...
November 02, 2023 10:14 ET | Source: Pharma Equity Group A/S

Forløb af ekstraordinær generalforsamling i Pharma Equity Group A/S

2. november 2023 Meddelelse nr. 43 Forløb af ekstraordinær generalforsamling i Pharma Equity Group A/S Pharma Equity Group A/S afholdte i dag ekstraordinær generalforsamling, hvor...
November 02, 2023 10:14 ET | Source: Pharma Equity Group A/S

Resolutions of the Extraordinary General Meeting of Pharma Equity Group A/S

2 November 2023 Announcement no. 43 Resolutions of the Extraordinary General Meeting of Pharma Equity Group A/S Pharma Equity Group A/S today held its Extraordinary General Meeting with...